Clinical Trial Update: Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer [Phase 2]

View source ↗

Summary

The Phase 2 safety study evaluating a tumor-targeting drug plus an immune therapy for renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Immune System Therapy
• Specific Tumor Target Drug

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: TERMINATED